Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia.

Seiffert, Dietmar; Stern, Andrew M; Ebling, William; Rossi, Richard J; Barrett, Yu Chen; Wynn, Richard; Hollis, Gregory F; He, Bokang; Kieras, Cathy J; Pedicord, Donna L; Cromley, Debra A; Hua, Tsushung A; Stein, Robert B; Daly, Robert N; Sferruzza, Anthony; Pieniaszek, Henry J; Billheimer, Jeffrey T

Seiffert, Dietmar; Stern, Andrew M; Ebling, William; Rossi, Richard J; Barrett, Yu Chen; Wynn, Richard; Hollis, Gregory F; He, Bokang; Kieras, Cathy J; Pedicord, Donna L; Cromley, Debra A; Hua, Tsushung A; Stein, Robert B; Daly, Robert N; Sferruzza, Anthony; Pieniaszek, Henry J; Billheimer, Jeffrey T.

Affiliation

Seiffert D; Bristol-Myers Squibb, Wilmington, DE 19880, USA. dietmar.seiffert@bms.com

Blood ; 101(1): 58-63, 2003 Jan 01.

Article in En | MEDLINE | ID: mdl-12393571

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Autoantibodies / Thrombocytopenia / Platelet Glycoprotein GPIIb-IIIa Complex / Amidines / Isoxazoles Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Blood Year: 2003 Document type: Article Affiliation country:

Search on Google

Add to My VHL

XML

PubMed Links